Is the Future Bleak for SAVA Stock Following Another Setback?

Cassava Sciences (SAVA) recently suffered yet another setback, which raises concern regarding its prospects. Nonetheless, simufilam is being evaluated for the treatment of Tuberous sclerosis complex (TSC)-related epilepsy. The company also has an investigational diagnostic product candidate, SavaDx, in its portfolio. SavaDX is a novel biomarker assay being studied for the detection of Alzheimer's disease from a small blood sample. Last week, the company announced that the phase III study REFOCUS-ALZ on lead ...